Affordable Access

deepdyve-link
Publisher Website

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

Authors
  • Nitz, U
  • Gluz, O
  • Zuna, I
  • Oberhoff, C
  • Reimer, T
  • Schumacher, C
  • Hackmann, J
  • Warm, M
  • Uleer, C
  • Runde, V
  • Dünnebacke, J
  • Belzl, N
  • Augustin, D
  • Kates, R E
  • Harbeck, N
Type
Published Article
Journal
Annals of Oncology
Publisher
Oxford University Press
Publication Date
Jan 01, 2014
Volume
25
Issue
1
Pages
75–80
Identifiers
DOI: 10.1093/annonc/mdt505
PMID: 24356620
Source
Medline
Keywords
License
Unknown

Abstract

DA treatment did not impact EFS or OS in routine adjuvant BC treatment.

Report this publication

Statistics

Seen <100 times